Etrumadenant

Phase 2Small molecule

Etrumadenant is an experimental drug being tested to treat cancer by blocking a protein called adenosine A2a that helps tumors hide from the immune system, allowing the body's immune cells to better fight the cancer.[1] Etrumadenant is currently being investigated across 6 indications[3], with its most advanced program in Phase 2.[1]

Etrumadenant is one of 206 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

205

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Ductal AdenocarcinomaRecruiting

Metastatic Prostate CancerRecruiting

Non-Small Cell Lung CancerActive, not recruiting

Prostate CancerTerminated

Rectal CancerRecruiting

Urothelial CarcinomaActive, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 2

Recruiting

Metastatic Prostate CancerPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Prostate CancerPhase 2

Terminated

Rectal CancerPhase 2

Recruiting

Urothelial CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

17 2

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 3

2 3

Pemetrexed+cisplatin

AstraZeneca

Phase 3

4 4

Etrumadenant

Arcus Biosciences

Phase 2

2 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Pancreatic Ductal Adenocarcinoma

NCT06048484

Phase 2Active, not recruiting

Dedifferentiated Liposarcoma

NCT05886634

Q3 2027

Phase 2Active, not recruiting

Urothelial Carcinoma

NCT05335941

Q4 2028

Phase 2Recruiting

Metastatic Prostate Cancer

NCT05915442

Q3 2029

Phase 2Recruiting

Lung Cancer

NCT05633667

Clinical

Trials by Indication[1]

Prostate Cancer3 trials

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1/2·NCT04381832·173 enrolled

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Terminated·CCoherus Oncology, Inc.·Phase 2·NCT05177770·16 enrolled

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Recruiting·DDavid Oh·Phase 2·NCT03821246·68 enrolled

Lung Cancer2 trials

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1·NCT03846310·77 enrolled

Study of Novel Treatment Combinations in Patients With Lung Cancer

Recruiting· Gilead logo

Gilead·Phase 2·NCT05633667·270 enrolled

Non-Small Cell Lung Cancer2 trials

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 2·NCT04262856·151 enrolled

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT04791839·30 enrolled

Advanced Malignancies1 trial

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1·NCT03629756·48 enrolled

Gastrointestinal1 trial

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1·NCT03720678·44 enrolled

10 more indications

Triple-Negative Breast Cancer1 trial

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1·NCT03719326·35 enrolled

Interaction1 trial

A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1·NCT05154136·20 enrolled

Locally Advanced Head and Neck Cancer1 trial

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

Withdrawn·JJennifer Choe·Phase 1·NCT04892875

Adult1 trial

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1·NCT05277012·24 enrolled

Metastatic Colorectal Cancer1 trial

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1/2·NCT04660812·227 enrolled

Metastatic Prostate Cancer1 trial

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Recruiting·CCatherine Spina·Phase 2·NCT05915442·23 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Recruiting·GGulam Manji·Phase 2·NCT06048484·60 enrolled

Dedifferentiated Liposarcoma1 trial

A Phase II Study of Adenosine Receptor (A2A and A2B) Inhibition (AB928) in Combination With Anti-PD-1 Therapy (AB122) in Patients With Advanced Dedifferentiated Liposarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05886634·16 enrolled

Urothelial Carcinoma1 trial

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05335941·10 enrolled

Rectal Cancer1 trial

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

Recruiting·WWeill Medical College of Cornell University·Phase 2·NCT05024097·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Etrumadenant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Etrumadenant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Etrumadenant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arcus Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Adenosine A2b Receptor Antagonist; Adenosine A2a Receptor Antagonist[2]
Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Arcus Biosciences

Etrumadenant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q4 2028

Q3 2029

Trials by Indication[1]

Prostate Cancer3 trials

Lung Cancer2 trials

Non-Small Cell Lung Cancer2 trials

Advanced Malignancies1 trial

Gastrointestinal1 trial

Triple-Negative Breast Cancer1 trial

Interaction1 trial

Locally Advanced Head and Neck Cancer1 trial

Adult1 trial

Metastatic Colorectal Cancer1 trial

Metastatic Prostate Cancer1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Dedifferentiated Liposarcoma1 trial

Urothelial Carcinoma1 trial

Rectal Cancer1 trial

References

Drug Info

Quick Facts

Related News